Cytosorbents (CTSO) Change in Receivables (2011 - 2026)
Cytosorbents (CTSO) posted Change in Receivables of -$310000.0 for Q1 2026, down 326.28% on a QoQ basis from $137000.0 in Q4 2025, and down 487.5% year-over-year from $80000.0 in Q1 2025.
Cytosorbents (CTSO) Change in Receivables (2011 - 2026) Analysis & Trends
Cytosorbents' Change in Receivables history runs 16 years deep, the most recent figure standing at -$310000.0 for Q1 2026.
- Quarterly Change in Receivables fell 487.5% year-over-year to -$310000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$813000.0 (down 185.43% YoY) and the FY2025 annual result came in at -$423000.0, down 124.59% from the prior year.
- Change in Receivables was -$310000.0 for Q1 2026 at Cytosorbents, down from $137000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $1.4 million in Q2 2023 and bottomed at -$1.3 million in Q3 2024.
- A 5-year average of $148296.4 and a median of $80000.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables surged 752.71% — and 2023, when it plunged 701.71%.
- Cytosorbents' Change in Receivables stood at $428400.0 in 2022, then sank by 183.49% to -$357670.0 in 2023, then jumped by 405.03% to $1.1 million in 2024, then tumbled by 87.44% to $137000.0 in 2025, then plunged by 326.28% to -$310000.0 in 2026.
- Business Quant data shows CTSO's Change in Receivables at -$310000.0 in Q1 2026, $137000.0 in Q4 2025, and -$303000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 42.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -444.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 287.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 117.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 117.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -124.60 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -141.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | -310,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -310,000.00 |
| Mar 31, 2026 | -310,000.00 |
| Dec 31, 2025 | 137,000.00 |
| Dec 31, 2025 | 137,000.00 |
| Sep 30, 2025 | -303,000.00 |
| Sep 30, 2025 | -303,000.00 |
| Jun 30, 2025 | -337,000.00 |
| Jun 30, 2025 | -337,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 1.09 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | -1.32 Mn |
| Sep 30, 2024 | -1.32 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 848,330.00 |
| Mar 31, 2024 | 848,330.00 |
| Dec 31, 2023 | -357,670.00 |
| Dec 31, 2023 | -357,670.00 |